Bifok

For the short-term treatment of acute, moderate pain that is not controlled by other analgesics such as paracetamol, ibuprofen or acetylsalicylic acid.

Do not use more than 6 tablets within 24 hours. The minimum time interval between taking the drug is 4 hours. Only for short-term use, the duration of treatment should not exceed 3 days. (see full Instructions for details).

Children: The use of the drug for children under 12 years of age is contraindicated.

Use during pregnancy or breastfeeding: Use during pregnancy or breastfeeding is contraindicated.

The ability to influence the speed of reaction when driving vehicles or other mechanisms: During treatment with the drug, you should refrain from driving vehicles or other mechanisms due to the possibility of such effects as dizziness, drowsiness, sedation, disorientation, confusion, etc. Regular long-term use of codeine leads to the development of dependence and tolerance and to the appearance of restlessness and irritability after stopping treatment.

Features of use and interaction with other medicinal products and other types of interactions: The medicinal product BIFOK® IS has a significant number of interactions with other drugs and features of use. Read the full Instructions for Medical Use of the drug before prescribing it.

Leave category: By prescription.

• Hypersensitivity to ibuprofen, codeine, or any of the components of the drug. Hypersensitivity reactions, which were previously observed after the use of NSAIDs.
• Active gastric and duodenal ulcer/bleeding or history of recurrences. Erosive-ulcerative lesions of the gastrointestinal tract in the exacerbation phase. gastrointestinal tract and perforations in the anamnesis associated with the use of NSAIDs.
• Cerebrovascular or other active forms of bleeding. Hematopoietic disorders of unknown etiology. Hemorrhagic diathesis or other blood coagulation disorders.
• Severe heart failure (NYHA class IV).
• Respiratory depression, obstructive diseases of the respiratory tract, bronchial asthma (during an asthmatic attack).
• Craniocerebral injuries or conditions accompanied by increased intracranial pressure.
• Conditions in which inhibition of peristalsis should be avoided or in which abdominal distension develops. Risk of paralytic intestinal obstruction, chronic constipation. Active inflammatory bowel disease.
• Severe liver failure. Severe renal failure. Severe dehydration caused by vomiting, diarrhea, or not drinking enough fluids.
• State of alcoholic intoxication.
• Simultaneous use with other NSAIDs, with monoamine oxidase (MAO) inhibitors and within 2 weeks after stopping the use of MAO inhibitors.
• Children under 12 years of age; children aged 12 to 18 years who undergo tonsillectomy and/or adenoidectomy to prevent obstructive sleep apnea; children aged 12 to 18 years with compromised respiratory function; women during pregnancy or breastfeeding; patients who have an ultra-rapid metabolism involving CYP2D6.

1 tablet contains ibuprofen 200 mg (0.2 g), codeine phosphate hemihydrate (based on codeine monohydrate) 10 mg (0.01 g).

10 tablets in a blister; 1 blister in a cardboard pack.

Store in the original packaging at a temperature not higher than 25 °C. Keep out of the reach of children.

"INTERKHIM" Limited Liability Company.

The location of the manufacturer and the address of the place of its activity: Ukraine, 65025, Odesa, 21st km. 40-A, Starokyivska road.

UA/14315/01/01 з 06.03.2020